Brazil China Japan RussiaSpain

A Platform for Innovation, Knowledge Sharing and Active Discussion – Cyprotex’s San Francisco ADME-Tox Workshop Draws in the Crowds

Our San Francisco ADME-Tox workshop was held today at the DoubleTree by Hilton Hotel at San Francisco Airport. We were fortunate to have an excellent line up of key opinion leaders from Forge Therapeutics, Gilead, Genentech, Paracelsus as well as Cyprotex who presented on their latest research and approaches used to drive their drug discovery projects. Speakers and topics included:

Zak Zimmerman, CEO and Co-founder, Forge Therapeutics

Forging ahead through Lead Op with New Chemistry targeting Metalloenzymes

Yurong Lai, Senior Director, Gilead

Applied PBPK Models to Predict Transporter Clearance

Aaron Fullerton, Scientist, Investigative Toxicology, Genentech

De-risking Hematopoietic Toxicity in Drug Discovery and Development – The Need for More Complex in vitro Tools

Rob Elsby, Principal Scientist, Head of Drug Transporter Sciences, Cyprotex

Quantitative Prediction of Drug-Drug Interactions with Common Statin Co-meds: A Framework for Decision-making within Drug Discovery/Development

Ron Aoyama, Senior Research Scientist, Gilead

Qualitative and Quantitative Analysis in Drug Metabolism

Tomomi Kiyota, Scientist, Investigative Toxicology, Genentech

Utility of Mitochondrial Respiration Assay Platforms for Lead Optimization during Drug Discovery and Development

Chris Strock, Associate Director, Biological Screening and Assay Development, Cyprotex

Developing MEA and High Content Assays for Prediction based on Organ-Specific Cellular Subtypes

Grace Furman, President and CEO, Paracelsus

Transitioning from Lead Optimization to Clinical Candidate: Are you Ready?

The one-day workshop focused on approaches and strategies for identifying and reducing ADME-Tox liability during lead optimization. Speakers presented their experiences and case studies within the pharmaceutical industry on how contemporary ADME-Tox tools can be deployed to select and optimize compounds with the greatest chance of success. Cyprotex supported the event as a contribution to continuing education and outreach to the scientific community. Over 160 people registered for the event highlighting the high level of interest in the topic area.

One of the speakers at the event, Zak Zimmerman PhD, CEO and Co-founder of Forge Therapeutics commented, ‘We have found this style of event to be an excellent platform for showcasing latest research and encouraging open discussion and knowledge sharing. This particular workshop in San Francisco provides a valuable networking opportunity for the local West Coast scientific community and helps forge new collaborations and alliances.’

Cyprotex would like to thank all the speakers and delegates for supporting the event and we look forward to seeing you at our workshops in the future!

Our next workshop will be held in Cambridge UK in May 2019.

Contact enquiries@cyprotex.com to be kept informed about future events.

Facebooktwitterlinkedin